Hugo Fry Email & Phone Number

Hamburg, De

Topas Therapeutics is advancing a highly differentiated and versatile approach to establish immune tolerance in autoimmune and immune-mediated diseases. Our proprietary, antigen-coupled nanoparticles, Topas Particle Conjugates, target liver sinusoidal endothelial cells to prompt anti-inflammatory immune responses and drive T cells toward tolerance.

Enschede, Nl

20Med’s mission is to establish a polymeric nanoparticles (PNP) platform that stands as a leading alternative to LNPs in the delivery of mRNAOur polymeric Nanoparticle platform is being applied to the development of several vaccines and therapeutics for human and animal health indications to help accelerate partnered programs toward clinical trials.

Boston, Massachusetts, Us

London, England, Gb

RQ Bio is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections.

Using breadth and depth as a Senior Leader in the Biopharmaceutical industry across Commercial, R&D and Industrial Affairs to advise Biotech organisations.

Paris, France, Fr

Sanofi is a global biopharmaceutical company committed to healthcare solutions from prevention to treatment. We turn scientific discoveries into medicine to improve human health. Every day we dedicate our most important resource, our people, to support patients and families through their health journey.____________________As the Managing Director for the UK , I lead our Commercial, Industrial, and R&D organization — delivering vision and strategy in innovative, global biopharmaceutical healthcare solutions.This dual role of Country Country Chair Sanofi UK and General Manager Sanofi Pasteur UK & Ireland encompasses the management of over 2,000 people and ~€800 million in turnover. My additional primary responsibilities include directing the Commercial Operations of the Sanofi Pasteur vaccines business with full P&L accountability.I represent the voice and face of Sanofi and provide global leadership in alignment with our dedication to improving access to healthcare and high-quality treatments, wherever people are in the world. . A visionary and driven leader, I strive each day to provide purpose to our diverse teams — working with people to build the tools to support our mission to Empower Life.» Strategic leader, expert, and spokesperson on Brexit» Chair of the Commercial Operations Committee of General Managers » Delivered a focused business prioritisation process and implementation of key transversal projects — leading the UK and Ireland to delivering the leading European geographical business performance in 2017» Developed a strategic business plan for vaccines and specialty care— designed to lead to a 4-fold increase in sales over the next 10 years

London, Gb

The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.____________________ABPI represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.Globally our industry is researching and developing more than 7,000 new medicines.The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.

London, Gb

The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.____________________ABPI represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.Globally our industry is researching and developing more than 7,000 new medicines.The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.

Fr

Sanofi Pasteur MSD was created to develop and commercialize vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. ____________________In 2015, I was selected to lead as Vice President and Chief Marketing Officer for Sanofi Pasteur MSD. As the executive in charge of leading commercial strategy and execution, I held responsibility for the organisation’s vaccines in Europe. I delivered executive leadership across the Business Franchises, Business Excellence, Pricing & Tenders, and Supply & Demand. » Chair of the Commercial Operations Committee of General Managers —leading the decision making across Franchises and Countries to meet top line and bottom line budget objectives» Achieved 105% of target in 2015» Led the launch readiness and launch of 5 new vaccines across Europe — propelling SPMSD into a new phase of growth of 5-year CAGR +7%.

Paris, France, Fr

Selected as the Global Project Leader for the Lixisenatide family of products, I provided visionary leadership in this high visibility role with a vertically integrated team of over 1000 staff. I directed this fully integrated project as a ‘company within a company’ —building strategy and managing complex business initiatives in alignment with Sanofi’s global marketplace goals.Here, I was fully accountable for all aspects of Research, Clinical Development, Registration, Industrial Development, Market Access, and Commercial Launch of 2 of the biggest opportunities in the Sanofi Diabetes and Sanofi Group pipeline.Comprehensive achievements in this role include leading the project successfully through phase 3 registration, market access and launch in Europe. I also developed a registration pathway with the FDA and launched a combination project on a fast track phase 3 and phase 3b programme.

Prague 10, Cz

As the General Manager for Zentiva, I held full responsibility and accountability for this autonomous branded generic affiliate of Sanofi in Russia — overseeing a staff of >500.In this role, I was a member of the Global Zentiva Leadership team where I reported directly to the President of the organisation.» Delivered highly effective leadership resulting in the turnover of >€100M and growth of +50%» Executed transformational strategies to bring the company in ahead of budget — during a complex period of integration

Paris, France, Fr

Running 3 Business Units in RussiaOncology, Diabetes, Cardio-Hospital

Paris, France, Fr

Full marketing responsibility across the affiliate portfolio.

Paris, France, Fr

Working across all Global Marketing Franchises and top 7 affiliates.

Suresnes, Fr

Finance

Leadership

Bsc, Chemistry